How Claude designed protein binders against scorpion neurotoxins
打开互动全文版(逐段中英对照 + 针对本篇提问)→本文介绍了一项实验:Claude Science 内部的一个研究模型在极少提示下,被要求针对蝎子神经毒素(一种被忽视的热带病靶点)设计从头微型结合剂。Claude 在 64 小时内基本自主工作,仅收到四次后续提示,便选定了毒素结构和热点、设定了质量阈值,并使用 12 种设计工具生成了 318,484 个设计,最终筛选出 180 个候选;在 Claude 的协助下又增加了 31 个。Adaptyv Bio 和 Twist Bioscience 的合作伙伴对所有 211 个设计进行了结合实验测试,其中 17 个达标,每个均针对单一毒素,针对 Cn2 的最强结合剂达到个位数纳摩尔亲和力。作者强调,中和作用尚未得到证实,因此并未宣称其可作为抗蛇毒血清,但外部专家称这项工作是有前景的第一步。结论是,设计紧密结合剂已不再是主要瓶颈;真正的挑战在于将结合剂转化为安全、可负担且广泛可及的药物。
This article describes an experiment in which an internal research model within Claude Science was tasked, with minimal prompting, to design de novo minibinders against scorpion neurotoxins, a neglected tropical disease target. Working largely autonomously over 64 hours with four follow-up prompts, Claude selected toxin structures and hotspots, set quality thresholds, and used 12 design tools to generate 318,484 designs, ultimately selecting 180 candidates; 31 more were added with Claude's help. Partners at Adaptyv Bio and Twist Bioscience experimentally tested all 211 designs for binding, and 17 met the criteria, each against a single toxin, with the strongest binders against Cn2 reaching single-digit nanomolar affinity. The authors stress that neutralization was not confirmed, so no antivenom is claimed, but outside experts called the work a promising first step. The conclusion is that designing tight binders is no longer the main bottleneck; the real challenge is turning binders into safe, affordable, and widely accessible drugs.
_**摘要:** 作为我们探索 Claude 如何加速药物发现工作的一部分,我们要求一个内部研究模型设计针对蝎子神经毒素的_ minibinders _(紧密附着于靶标的小型蛋白质)。Claude 根据我们的提示和四次后续交互进行工作,这些是我们与金融投资研究公司 Citrini Research 合作开发的。Adaptyv Bio 和 Twist Bioscience 的团队对 211 个设计进行了结合实验测试。其中,17 个符合我们的标准。我们将发布所有 211 个设计及其数据,作为该领域的资源。_
_**Summary:** As part of our work experimenting with how Claude can help accelerate drug discovery, we asked an internal research model to design_ minibinders _(small proteins that attach tightly to a target) against scorpion neurotoxins. Claude worked from our prompt and four follow-ups, which we developed in collaboration with the financial investment research firm Citrini Research. Teams at Adaptyv Bio and Twist Bioscience experimentally tested 211 designs for binding. Of these, 17 met our criteria. We’re releasing all 211 designs and their data as a resource for the field._
八月份,我们展示了 Claude 在获得单个提示后如何设计蛋白质 minibinders。在我们发布那些结果的一个月前,Citrini Research 的团队向我们提出了一个有趣的问题:Claude(以及更广泛的人工智能药物发现)能否使一群有动力的非专家解决人类健康中的一个真正问题?我们的生命科学研究团队成员开始回答这个问题,首先与 Claude 一起头脑风暴问题。我们最终决定请求 Claude 帮助设计针对蝎子神经毒素的新型蛋白质结合剂,希望它们有朝一日能用于开发蝎子抗蛇毒血清。
In August, we showed how Claude designed protein minibinders after being given a single prompt. A month before we released those results, a team from Citrini Research had approached us with an interesting question: could Claude (and AI drug discovery more generally) enable a group of motivated nonexperts to tackle a genuine problem in human health? Members of our life science research team set out to answer this, first by brainstorming problems with Claude. We landed on asking for Claude’s help designing novel protein binders against scorpion neurotoxins, with the hope that they could one day be used to develop a scorpion antivenom.
每年有 120 万人或更多人被蝎子蜇伤,导致超过 3,250 人死亡,其中大多数是医疗条件有限地区的儿童。新疗法的制造成本高昂,而且也不太可能收回开发成本。由于投资如此之少,蝎子中毒被描述为一种被忽视的热带疾病。
Scorpions sting 1.2 million people or more every year, resulting in more than 3,250 deaths, mostly among children in parts of the world with limited access to medical care. New treatments are expensive to make, and are also unlikely to earn back the cost of developing them. With so little investment, scorpion envenomation has been described as a neglected tropical disease.
我们首先给 Claude 提供了与之前蛋白质结合剂研究中相同的提示,并与 Citrini 一起进行了修改。\^{1}\ 在接下来的 64 小时里,一个内部研究模型在 Claude Science 中运行,主要自主工作,尽管我们通过四次后续交互指导了它的工作。在我们的监督下,Claude 分析了研究数据,生成了图表,并起草了最终报告。
We started by giving Claude the same prompt we’d used in our earlier protein-binder study, after modifying it with Citrini.\^{1}\ Over the next 64 hours, an internal research model, operating within Claude Science, worked mainly autonomously, although we directed its work with four follow-ups. Under our supervision, Claude analyzed the research data, generated the figures, and drafted the final report.
Claude 的设计活动产生了 17 种蛋白质结合剂,每种都能与四种已知对人类危险的蝎子神经毒素之一结合。在整个过程中,Claude 生成了 318,484 个蛋白质设计,并选择了其中 180 个进行测试。我们的团队在 Claude 的帮助下又添加了 31 个。我们的合作伙伴 Adaptyv Bio 和 Twist Bioscience(两家合同研究组织(CRO))对所有 211 个设计进行了实验室测试,以查看它们是否与设计针对的毒素结合,其中 17 个设计符合我们对结合剂的标准。我们尚未确认这些结合剂是否在细胞环境中中和蝎毒,因此我们不声称已经生产出抗蛇毒血清。
Claude’s design campaign produced 17 protein binders that each bind to one of four scorpion neurotoxins that are known to be dangerous to humans. Throughout the process, Claude generated 318,484 protein designs and selected 180 of them for testing. Our team added 31 more, with Claude’s help. Our partners at Adaptyv Bio and Twist Bioscience, two contract research organizations (CROs), lab-tested all 211 designs to see if they would bind to the toxins they were designed against, and 17 designs met our criteria for a binder. We have not confirmed whether these binders neutralize scorpion venom in a cellular environment, so we do not claim to have produced an antivenom.
我们将 Claude 的工作成果送交两位外部专家 Susana Vázquez Torres 和 Timothy P. Jenkins 评审,他们表示这项工作是一个有前景的开端。如果 AI 如今能在数天内针对若干难以靶向的毒素设计出可信的结合体(binder),并能在数周内在实验室中得到验证,那么理论上这可以加速蛇伤中毒及其他被忽视疾病的发现进程。一如既往,挑战在于如何将这些结合体转化为安全、可负担且广泛可及的药物。
We sent Claude's work to two outside experts, Susana Vázquez Torres and Timothy P. Jenkins, who said they felt this work was a promising first step. If AI can now design credible binders against several hard-to-target toxins in days and they can be confirmed in the lab within weeks, this could, in theory, speed up discovery for envenomation and other neglected diseases. The challenge, as always, is turning those binders into safe, affordable, and widely accessible drugs.
我们在技术报告中提供了更多细节,并公开了全部 211 个设计及其数据。
We share more detail in our technical report, and are making all 211 designs and their data available.
针对几乎任何靶点设计结合体已不再显得不切实际。我们如今能够以惊人的速度获得结合非常紧密的结合体,而结合本身已不再是主要瓶颈。对于蛇和蝎子等有毒动物——其咬伤和蜇伤导致大量人群死亡或严重受伤,尤其是在服务不足的地区——真正的影响将来自攻克治疗流程中超出结合环节的部分。挑战在于利用这些非凡的工具,开发出能够成为真正药物的分子,即安全、可负担且广泛可及的药物。
Designing a binder against almost any target no longer seems unrealistic. We can now obtain very tight binders remarkably quickly, and binding itself is no longer the main bottleneck. For venomous animals such as snakes and scorpions, whose bites and stings kill or seriously injure large numbers of people, particularly in underserved regions, the real impact will come from tackling the parts of the therapeutic pipeline that go beyond binding. The challenge is to use these extraordinary tools to develop molecules that can become real drugs, ones that are safe, affordable, and widely accessible.
_**Susana Vázquez Torres**,西班牙国家癌症研究中心(CNIO)结构生物学项目博士后研究员,西班牙马德里。_
_**Susana Vázquez Torres**, Postdoctoral Researcher, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain._
蝎毒含有多种蛋白质神经毒素。最可能危害或致死人类的神经毒素会附着在**钠通道**上,钠通道是嵌入神经细胞膜的大型蛋白质,使神经细胞能够放电。当钠通道受到破坏时,神经会错误地放电——这会释放大量应激化学物质,如肾上腺素。严重时,这可能导致心力衰竭和肺部积液,偶尔导致死亡。
Scorpion venom contains multiple protein neurotoxins. The neurotoxins that are most likely to harm or kill humans attach to _sodium channels_, large proteins embedded in the membranes of nerve cells that allow them to fire. When sodium channels are disrupted, nerves fire at the wrong time—this releases large amounts of stress chemicals, like adrenaline. In severe cases, this can cause heart failure and excess fluid buildup in the lungs, occasionally resulting in death.
目前有一些针对蝎子蜇伤的抗蛇毒血清。它们通常使用免疫动物的抗体制造,这一过程可能需要数月。从数千只蝎子中提取毒液,用于免疫马匹;然后科学家从马血中纯化产生的抗体。传统抗蛇毒血清在早期给药时可能有效,但通常仅对少数神经毒素有效。它们生产成本高昂,在许多地区价格昂贵或供应短缺。
There are some antivenoms available for scorpion stings. They’re generally made using the antibodies of immunized animals, a process that can take months. Venom is milked from thousands of scorpions and used to immunize horses; scientists then purify the resulting antibodies from the horses’ blood. Traditional antivenoms can work when given early, but they’re usually effective for only a small number of neurotoxins. They’re also expensive to produce, and in many regions are costly or in short supply.
**从头设计**提供了一种潜在的解决方案。结合蛋白是一种能紧密附着于特定靶标的分子;抗体是一种天然的例子。原则上,靶向神经毒素上附着钠通道部分的结合蛋白可以阻止毒素到达通道。在从头设计中,蛋白质结合蛋白是针对特定靶标从零开始生成的。这些结合蛋白通过计算设计,并可以针对药物样性质(如效力和稳定性)进行优化,这可能使它们更容易在蜇伤最常发生的地区供应。
_De novo_ design offers a potential solution. A binder is a molecule that attaches tightly to a specific target; antibodies are one natural example. In principle, a binder that targets the part of a neurotoxin that latches onto sodium channels could stop the toxin from reaching the channel. In _de novo_ design, protein binders are generated from scratch against a specific target. These binders are designed computationally and can be optimized for druglike properties such as potency and stability, which could make them easier to supply in regions where stings most often occur.
我们的方法受到早期工作的启发,该工作设计了**从头**蛋白质,中和了蛇神经毒素并保护了小鼠。据我们所知,尚未有针对蝎神经毒素的从头设计结合蛋白的报道。
Our approach was inspired by an earlier effort that designed _de novo_ proteins that neutralized snake neurotoxins and protected mice. To our knowledge, no _de novo_-designed binders against scorpion neurotoxins have been described.
在这项研究中,我们选择靶向四个地区的五种蝎毒神经毒素:墨西哥(Cn2)、巴西(Ts1)、北非(AaH I 和 AaH II)以及中东(LqhIII)。我们还选择将设计瞄准每种毒素的通道结合位点。Claude 通过搜索蛋白质数据库(PDB)以及 AlphaFold 数据库(AFDB)来挑选用于设计的毒素结构。对于每种毒素,它选择了五个**热点**,即毒素上特定的氨基酸位置,其结合蛋白设计旨在附着于这些位置。
For this campaign, we chose to target five scorpion-venom neurotoxins across four regions: Mexico (Cn2), Brazil (Ts1), North Africa (AaH I and AaH II), and the Middle East (LqhIII). We also chose to aim the designs at each toxin’s channel-binding site. Claude picked the toxin structures to use for design by searching the Protein Data Bank (PDB) as well as the AlphaFold database (AFDB). For each toxin, it selected five _hotspots_, specific amino acid positions on the toxin that its binder designs were meant to latch onto.
为了考察 Claude 能走多远,我们要求它设计四类结合蛋白:分别针对五种毒素各自的结合蛋白;靶向 β 家族毒素 Ts1 和 Cn2 的结合蛋白;靶向 α 家族毒素 AaH II、AaH I 和 LqhIII 的结合蛋白;以及同时靶向全部五种毒素的结合蛋白。
To see how far Claude could go, we asked it to design four kinds of binders: binders against each of the five toxins individually; binders that targeted the β-family toxins Ts1 and Cn2; binders that targeted the α-family toxins AaH II, AaH I, and LqhIII; and binders that targeted all five toxins simultaneously.
在短短几天内并行设计出针对五种毒素的可信结合蛋白,充分展示了我们在治疗发现领域所见证的 AI 驱动的范式转变。对于动物蜇伤这类被忽视的疾病而言尤其如此——由于商业激励不足,这些领域长期缺乏创新。能够以智能体式的方式应对动物毒素这一格外宽广的靶点空间,可显著加速发现进程,并使切实可行的治疗方案更近一步。
Designing credible binders against five toxins in parallel, in a matter of days, is a great showcase of the AI-driven paradigm shift we are seeing in therapeutic discovery. This is especially true for neglected diseases such as animal envenomings, which have been largely starved of innovation due to low commercial incentives. Being able to agentically tackle the uniquely broad target space across animal toxins provides a significant speed-up in discovery, and brings realistic therapeutic solutions much closer.
_**Timothy P. Jenkins**,丹麦技术大学副教授。_
_**Timothy P. Jenkins**, Associate Professor, Technical University of Denmark._
我们最初的提示词定义了神经毒素靶点、蛋白质设计与折叠工具,以及新颖性、评分和过滤的规则。除了选择结构和氨基酸热点外,Claude 还设定了设计必须达到的质量阈值,决定了依赖每种可用设计工具的程度,并制定了针对多种毒素设计结合蛋白的策略。
Our initial prompt defined the neurotoxin targets, the protein design and folding tools, and the rules for novelty, scoring, and filtering. Beyond choosing the structures and amino acid hotspots, Claude also set the quality thresholds a design had to clear, decided how much to lean on each available design tool, and developed the strategies for designing binders against multiple toxins.
最终,Claude 使用了 12 种设计工具生成了 318,484 个设计,并过滤掉任何与毒素或已知蛋白质相似的设计。Claude 对 553,052 个设计-毒素对进行了共折叠和筛选,将每个对预测为一个复合物的结构。在我们给出初始提示词 64 小时后,它生成了最终的 180 个设计列表。该任务使用了约 10,000 GPU 小时。^2
Ultimately, Claude used 12 design tools to generate 318,484 designs, filtering out any that resembled a toxin or a known protein. Claude co-folded and screened 553,052 design-toxin pairs, predicting each pair’s structure as one complex. Sixty-four hours after we gave Claude our initial prompt, it produced its final list of 180 designs. The campaign used on the order of 10,000 GPU hours.^2
在第一次提示词之后,Claude 自主工作了 24 小时。其结果鼓励我们提示 Claude 继续其任务并寻找更好的设计。我们的后续提示词主要集中于指导 Claude 设计多毒素结合蛋白。Claude 仅在我们的第三次后续提示后才选择了 180 个设计中的大部分——包括我们最强的结合蛋白(Cn2-B1)。应我们的要求,Claude 将蛋白质序列发送给 Twist Bioscience(在电子邮件中表明它们是由 Claude 编写的),该公司生产了这些蛋白质,以观察它们与毒素的结合效果。我们后来与 Claude 合作又添加了 31 个设计,使总数达到 211 个设计:60 个针对单一毒素的设计(每种毒素 12 个),30 个针对两种 β 家族毒素的设计,30 个针对三种 α 家族毒素的设计,以及 91 个针对所有五种毒素的设计。
Claude worked autonomously for 24 hours following our first prompt. Its results encouraged us to prompt Claude to continue its campaign and look for better designs. Our follow-up prompts were mainly focused on directing Claude to design a multitoxin binder. Claude selected most of the 180 designs—including our strongest binder (Cn2-B1)—only after our third follow-up. At our request, Claude sent the protein sequences to Twist Bioscience (in emails indicating they were written by Claude), which produced the proteins in order to see how well they would bind to the toxins. We later worked with Claude to add another 31 designs, increasing the total to 211 designs: 60 designs against a single toxin (12 per toxin), 30 designs against the two β-family toxins, 30 designs against the three α-family toxins, and 91 designs against all five toxins.
在我们团队评估的 211 个设计中,有 17 个符合我们结合蛋白的标准,每个都针对单一毒素。针对多种毒素的设计中没有一个符合一种以上毒素的标准。(除了受其当前能力的限制外,Claude 在这方面遇到困难可能有很多解释,包括我们的提示词、可用设计工具的局限性,甚至多毒素设计的生物学可行性。)七个设计是针对 Cn2 的结合蛋白,四个针对 AaH II,四个针对 AaH I,两个针对 LqhIII。在 60 个单一毒素设计中,有 11 个是结合蛋白(18%)。这一比率与典型的蛋白质设计任务一致,包括我们之前的工作。
Of the 211 designs our teams assessed, 17 met our criteria for a binder, each against a single toxin. None of the designs made against multiple toxins met our criteria for more than one. (Beyond being limited by its current capabilities, there could be many explanations for why Claude struggled with this, including our prompting, the limitations of available design tools, and even the biological feasibility of multitoxin design.) Seven designs were binders against Cn2, four against AaH II, four against AaH I, and two against LqhIII. Among the 60 single-toxin designs, 11 were binders (18%). This rate is consistent with typical protein design campaigns, including our previous work.
在完成设计生成后,我们将设计发送给 Adaptyv Bio 和 Twist Bioscience 进行结合测试。两个团队分别在其实验室中生产了这些设计,但采用了不同的形式。Adaptyv Bio 在无细胞系统中表达这些设计,该系统使用从细菌中提取的蛋白质制造机制而非活细胞。Twist Bioscience 在哺乳动物细胞(此处为人肾细胞)中表达这些设计,并将其与 Fc(抗体的茎部)融合。这些是测量潜在结合过程的互补方法,我们将它们结合起来以提高对结果的信心。
After completing the campaign, we sent the designs to Adaptyv Bio and Twist Bioscience to test them for binding. Each group produced the designs in their labs, but in different formats. Adaptyv Bio expressed them in a cell-free system, which uses protein-making machinery extracted from bacteria rather than living cells. Twist Bioscience expressed the designs in mammalian cells (in this case, human kidney cells) as fusions to Fc, the stem of an antibody. These are complementary ways to measure the underlying binding process, and we combined them in order to improve confidence in our results.
两个实验室均通过表面等离子体共振(SPR)测量结合,其中毒素流经设计,同时 SPR 仪器实时追踪毒素与设计结合和解离的速度。得到的迹线称为传感图,产生一个称为解离常数(KD)的测量值,该值衡量结合强度(或亲和力)。KD 越低,结合越紧密。
Both labs measured binding by surface plasmon resonance (SPR), in which a toxin flows over the design while the SPR instrument tracks in real time how quickly a toxin binds to and detaches from it. The resulting trace, called a sensorgram, produces a measurement known as the dissociation constant (KD), which is a measurement for binding strength (or affinity). The lower the KD, the tighter the binding.
在评估所得设计时,我们设定了严格的标准来标记设计是否与毒素结合。设计需要在两个实验室均为命中——即需要在每个重复中显示与该毒素结合的证据,且每个 KD 需要为 1 µM 或更低。我们还要求设计对 CLEC12A(一种无关的人类蛋白,用于测量脱靶结合或“粘性”)不显示信号。
When it came to evaluating the resulting designs, we set out strict criteria for labeling a design a binder against a toxin. The design needed to be a hit at both labs—that is, it needed to show evidence of binding against that toxin in every replicate, and every KD needed to be 1 µM or tighter. We also required that the design show no signal against CLEC12A, an unrelated human protein used to measure off-target binding or “stickiness.”
抗体和纳米抗体仍是 _de novo_ 设计需要超越的标准。已有三种此类分子报道了对 Cn2 或 AaH II 的亲和力(KD)低于 1 nM(纳摩尔),并已被证明能保护小鼠免受蝎毒素侵害。
Antibodies and nanobodies remain the standard for _de novo_ designs to beat. Three such molecules have reported affinities (KD) below 1 nM (nanomolar) against Cn2 or AaH II, and they have been shown to protect mice from scorpion toxins.
我们最强的两个结合蛋白,我们称之为 Cn2-B1 和 Cn2-B2,靶向 Cn2——一种来自墨西哥蝎 _Centruroides noxius_ 的神经毒素。它们在 Adaptyv Bio 和 Twist Bioscience 两处均能紧密结合 Cn2,亲和力(KD)处于个位数纳摩尔范围。
Our two strongest binders, which we call Cn2-B1 and Cn2-B2, target Cn2, a neurotoxin from the Mexican scorpion _Centruroides noxius_. They each bound Cn2 tightly at both Adaptyv Bio and Twist Bioscience, with affinities (KD) in the single-digit nanomolar range.
判断两个分子(例如,一个抗体和一个小蛋白)是否结合靶标上同一位点的一种方法是进行 _竞争实验_,该实验检验两种结合蛋白能否同时附着到靶标上。如果一种分子的存在降低了另一种分子的结合,那么它们很可能竞争同一位点。
One way to find out whether two molecules (e.g., an antibody and a miniprotein) bind the same site on a target is with a _competition experiment,_ which tests whether both binders can attach to the target at the same time. If the presence of one molecule reduces the other molecule's binding, then they likely compete for the same binding site.
我们的竞争实验表明,我们的 Cn2 结合蛋白各自附着在与一种名为 LR 的抗体相同或相近的 _表位_(结合位点)上,该抗体已被报道能在小鼠中中和 Cn2。LR 的结合位点覆盖了 Cn2 中附着于钠通道并导致神经错误放电的部分。我们尚未在细胞环境或活体动物中测试我们最强的结合蛋白 Cn2-B1 和 Cn2-B2,但它们与 LR 竞争这一事实表明它们很可能能中和 Cn2。
Our competition experiments suggest our Cn2 binders each attach on or near the same _epitope_ (binding site) as an antibody called LR, which has been reported to neutralize Cn2 in mice. LR's binding site covers the part of Cn2 that attaches to the sodium channel and causes nerves to misfire. We have not tested our strongest binders, Cn2-B1 and Cn2-B2, in a cellular environment or in live animals, but the fact that they compete with LR suggests that they will likely neutralize Cn2.
我们的结果表明,结合仅针对**重组**毒素——这些毒素是在实验室中根据每种毒素的基因培育而成,而非从蛇毒中纯化获得。本研究的两大局限在于:我们未测试任何设计在**体外**(针对实验室培养的细胞)的中和效果,也未测试其在**体内**(如小鼠等活体动物)的功效。
Our results show binding only against _recombinant_ toxins, which are grown in the lab from each toxin's gene rather than purified from venom. The two biggest limitations of this study are that we didn't test any design for neutralization _in vitro_ (against cells grown in the lab) or for efficacy _in vivo_ (in living animals, such as mice).
如果要将某一设计推进至疗法阶段,Cn2-B1 将是我们最强的候选之一。不过,首先我们需要确认该设计也能结合从蛇毒中纯化的毒素。随后,我们将通过膜片钳记录(可测量通过钠通道的电流)在**体外**评估其功能,以观察它是否能阻止毒素作用于通道。接着,我们需要在小鼠中测试该结合剂,以观察它是否确实具有保护作用。除了中和毒素外,治疗方案还必须安全、稳定、可负担,并能在发生螫伤的地点获得。要让治疗惠及患者,还需要临床医生、资助者和政策制定者的合作。
If we were to advance one design toward a therapy, Cn2-B1 would be one of our strongest candidates. First, though, we would need to confirm the design also binds toxin purified from venom. We would then assess it for function _in vitro_ with patch-clamp recordings (which can measure the electrical current passing through sodium channels) to see whether it stops the toxin from acting on the channel. Then, we would need to test the binder in mice to see whether it actually protects them. Beyond neutralizing the toxin, a treatment must also be safe, stable, affordable, and available where stings occur. Reaching patients will also take cooperation from clinicians, funders, and policymakers.
我们正在公开全部 211 个设计及其结合数据,以便其他研究人员能在我们的工作基础上继续推进。我们希望,这一对 Claude 能力的展示以及我们公开的数据,将有助于加速抗蛇毒血清设计的进一步研究。
We are releasing all 211 designs and their binding data so that other researchers can build on our work. We hope this demonstration of Claude's capabilities, along with the data we are releasing, will help accelerate further research into antivenom design.